Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921913 | 0.84 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL22777865 | 0.84 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL5904008 | 0.83 | MAPT (0.75) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL6075470 | 0.82 | SMN1; SMN2 (0.74) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL9099028 | 0.81 | MAPT (0.71) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL27598434 | 0.80 | MAPT (0.50) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL7302053 | 0.80 | MAPT (0.73) | MAPTALDH1A1HTTKDM4ENPSR1 | |
| SCHEMBL27022350 | 0.79 | MAPT (0.71) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL27921853 | 0.78 | LMNA (0.68) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL6074803 | 0.78 | TSHR (0.56) | MAPTSMN1; SMN2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| CN-1455771-A | Cyclic amine phenyl Beta-3 adrenergic receptor agonists | WYETH LTD (US) | 2003-11-12 | — | — | CN | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885SMN1; SMN2 3999/4885ALDH1A1 1091/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885SMN1; SMN2 3999/4885ALDH1A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.